Experimental cell therapy takes aim at Hard-to-Treat pancreatic cancer

This early-phase trial tests a personalized cell therapy called TCR-T cells, engineered to recognize and attack cancer cells with a specific KRAS mutation. Up to 18 adults with advanced pancreatic cancer who have exhausted standard treatments will receive a single infusion of these cells after a short chemotherapy prep. The study primarily checks safety and whether the tumors shrink, while also measuring how long the cells last in the body.